68 results about "Fatty acid binding" patented technology

The invention relates to a medical diagnostic reagent, in particular to a quick detection reagent for the early diagnosis of acute myocardial infarction and a test strip. The invention provides a double-index united detection reagent containing a specific antibody resisting a human heart-type fatty acid binding protein H-FABP and a human cardiac troponin cTnI. The invention also provides a colloidal gold labeling immunological chromatographic test strip containing the specific antibody resisting the H-FABP and the cTnI, which is used for quickly detecting the acute myocardial infarction. The double-index united detection reagent can carry out early diagnosis on a patient having the acute myocardial infarction, can also prevent the missed diagnosis of a patient having long-time chronic myocardial infarction with mild symptoms and better solves the influence caused by a difference existing in the detection time. The colloidal gold labeling immunological chromatographic test strip provides a quick, convenient, cheap and practical detection tool for the early diagnosis of the acute myocardial infarction, is hopefully used for hospitals at all levels and can also be used for the self monitoring of the patient.

A method of diagnosing the stage or aggressiveness of cancer and particularly breast and prostate cancer by measuring the deviation of levels of fatty acid binding proteins in mammalian tissue or body fluids from normal levels of fatty acid binding proteins. The invention relates to a family of key proteins called fatty acid binding proteins which are involved in metabolism of AA and other lipids and how they affect the proliferation of cancer cells.

The invention provides a compound and application of the compound and the pharmaceutically acceptable salt thereof or a stereo isomer or a prodrug molecule thereof in preparing a medicament for treating or preventing metabolic diseases, wherein the compound has the structural characteristic of a general expression I and is used as a novel fat cell type fatty acid binding protein FABP inhibitor. The compound having the structural characteristic of the general expression I can provide a new selection for the clinical prevention and treatment of the following diseases: 1. type II diabetes, 2. hyperglycemia, 3. hypoglycemia tolerance, 4. insulin resistance, 5. adiposity, 6. lipid turbulence, 7. blood-lipoid imbalance, 8. hyperlipaemia, 9. hypertriglyceridemia, 10. hypercholesterolemia, 11. low high-density protein level, 12. overhigh low-density protein level, 13. atherosclerosis and secondary diseases thereof, 14. hemadostenosis, 15. abdominal obesity, 16. a metabolic syndrome and 17. fatty liver.

The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.

The physiological regulation of intake, growth and energy partitioning in animals is under the control of multiple genes, which may be important candidates for unraveling the genetic variation in economically relevant traits in beef production. The present invention relates to the identification of single nucleotide polymorphisms (SNPs) within the bovine genes encoding fatty acid binding proteins and their associations with economically relevant traits in beef production. The invention further encompasses methods and systems, including network-based processes, to manage the SNP data and other data relating to specific animals and herds of animals, veterinarian care, diagnostic and quality control data and management of livestock which, based on genotyping, have predictable meat quality traits, husbandry conditions, animal welfare, food safety information, audit of existing processes and data from field locations.

The invention provides infant formula milk powder rich in milk fat globule membrane protein and phospholipid. By adding alpha-lactalbumin, milk fat globule membrane and a physiological activator, suchas bifidobacterium animalis Bb-12, milk fat globule membrane lipids and protein, N-acetylneuraminic acid (sialic acid), SN-2 structure lipid, human milk oligosaccharides (HMOs) and human milk oligose(HMO). By simultaneously adjusting the using amount ratio of all the components, especially sphingomyelin, gangliosides, the milk fat globule membrane protein, the human milk oligosaccharides, the human milk oligose, adiponectin and lysozyme, and the proportion between mucin, xanthine oxidoreductase, mucin 15, CD 36, butyrophilin, adipose differentiation-related protein and fatty acid binding proteins, the content of the active ingredients in the milk powder is closer to the content of active ingredients in human milk, the constitution of the infant formula milk powder is optimized, and the formula milk powder obtained by using the method is closer to the human milk.

Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, especially CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using a specific antibody thereto. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.

Metastasis stem cells are targeted through a fatty acid receptor. Blockers or inhibitors of CD36 activity or expression are for the treatment of oral squamous cell cancer (OSCC), particularly for the treatment of generated metastases and for diminishing generation from primary tumors. Apart from shRNAs, anti-CD36 antibodies are provided as blockers or inhibitors, especially those that block the binding of CD36 to oxidized LDL and fatty acids and their incorporation into cells, because the promotion of their transport is indicated as the mechanism by which CD36 promote metastases dissemination and growth. A method identifies candidates to anticancer agents, particularly for OSCC metastasis, among those that promote in CD36+ cells, in vivo or in vitro, effects associated to CD36 depletion or blocking such as decrease of growth accumulation of lipid droplets and decrease of size in the case of metastases.

This invention relates to agricultural compositions that find particular use as a fungicide composition. The fungicide composition can include one or more fatty acids and one or more organic acids different from the fatty acid. The organic acid can but need not exhibit any fungicidal activity; however, when combined with a fatty acid, the organic acid functions as a potent synergist for the fatty acid as a fungicide. Additionally, the fungicide composition can include other components such as emulsifiers, adjuvants, surfactants and diluents. The fungicide composition significantly reduces or prevents the fungal infection of cash crops including vegetables, fruits, berries, seeds, grains and at higher application rates, can also be used as a harvest aid or desiccant for harvested crops such as potatoes.

The invention discloses a liver-type fatty acid binding protein detection reagent box. The box comprises seven storage assemblies which are used for storing L-FABP correcting products, L-FABP qualitycontrolling products, enzyme compound working liquid, magnetic bead working liquid, cleaning liquid, substrate solutions and pretreatment reagents respectively; the magnetic bead working liquid comprises carboxyl magnetic beads with marked L-FABP antibodies, and the enzyme compound working liquid comprises L-FABP antibodies marked by alkaline phosphatase. The invention further discloses a detection method for detecting liver-type fatty acid binding proteins. According to the detection reagent box, the minimum detection limit is 0.5 ng/ml, the linear range is 0.5-500 ng/ml, the detection sensibility is high, the linear range is wide, the detection time length is shortened to 15 minutes, and the detection procedures are simplified.

The present invention relates to a population of monodisperse magnetic nanoparticles with a diameter between 1 and 100 nm which are coated with a layer with hydrophilic end groups. Herein the layer with hydrophilic end groups comprises an inner layer of monosaturated and/or monounsaturated fatty acids bound to said nanoparticles and bound to said fatty acids, an outer layer of a phospholipid conjugated to a monomethoxy polyethyleneglycol (PEG) comprising a hydrophilic end group,

or comprises a covalently bound hydrophilic layer bound to said nanoparticles.

The invention relates to an additive for biogas fermentation. The additive is mixed from the following components in percentage by weight: 10%-50% of polysaccharide substances, 15%-75% of protein substances, and 0-15% of fatty acid conjugate or nitrogen substances. The additive for the biogas fermentation can be adopted for prompting the fermenting materials to quickly enter a glycolysis way under an anaerobic condition for continuously degrading and quickly and efficiently generating biogas. According to the experimental data, only 0.3Kg/m<3>-0.6Kg/m<3> of additive is added in feed liquid of a biogas digester according to the size of the biogas digester, so that a pH value of the feed liquid can be accelerated to tend to normal, so that the biogas can be generated 15-60 days ahead of the normal fermentation time; meanwhile, the gas generation rate can be improved.

The invention relates to the expression and purification of human heart-type fatty acid-binding protein in escherichia coli DH5 alpha, which belongs to the biological technical field, the expression and purification comprises: firstly, preparing an oligonucleotide primer, secondly, amplifying with RT-PCR and determining a sequence, thirdly, constructing recombinant expression plasmids, fourthly, expressing heart-type fatty acid-binding protein through inducing, and fifthly, extracting and purifying the human heart-type fatty acid-binding protein. The expression and the purification of the invention have the beneficial effect that a PL promoter is enabled to enter a complete inhibitory state. H-FABP protein is expressed in PBV220 through utilizing the characteristic. We optimize the temperature and the time in the expression process, bacteria is increased under the temperature of 30DEG C, and high level expression is obtained through inducing for 5 hours under the temperature of 42 DEG C. The successful clone and expression of the human heart-type fatty acid-binding protein lay the foundation of further researching the significance of the heart-type fatty acid-binding protein in the diagnosis and therapeutic effect evaluating of diseases.

An edible oil containing proportionally fatty acids, especially the linolenic acid, is prepared through biologic enzyme catalyzed esterifying reaction between soybean oil and N3 (or N6)-series poly-unsaturated-fatty acid including proportionally saturated fatty acid, mono-unsaturated-fatty acid, poly-unsaturated-fatty acid and linolenic acid.

The subject application comprises methods for determining the occurrence of an ischemic event in a subject by determining an ischemia score based on the amount of at least two ischemia modified albumin markers. The ischemia modified albumin markers include complexes of fatty acids bound to albumin, albumin molecules with open Cys34 sites, albumin molecules that are products of oxidation at Cys34, albumin molecules with altered conformation or altered divalent metal binding due to the conformational change or oxidation at Cys34, and albumin molecules that have been oxidized at the N-terminus. Also included in the invention are ligands to each of the foregoing ischemia modified albumin markers. Further included are methods of determining the occurrence of an ischemic event by determining the amount of fatty acid that is complexed to albumin in a patient sample. In another embodiment, an ischemic event is determined by quantitating the relative amounts of reduced and oxidized forms of albumin Cys34. In an additional embodiment, an ischemic event is determined by observing whether a shift in albumin conformation has occurred which would reflect oxidized Cys34. Further, the invention comprises a method of determining an ischemic event by determining the amount of metal ion bound to the albumin metal ion binding sites.

The invention provides a homogeneous immunometric fluorescent compound set for quickly and quantificationally detecting heart fatty acid binding-proteins (FABP) and a preparation method of the homogeneous immunometric fluorescent compound set. The homogeneous immunometric fluorescent compound set comprises a rare-earth element chelate marked anti-FABP monoclonal antibody, a near infrared fluorescent compound marked anti-FABP monoclonal antibody and FABP calibrators with series concentration. The homogeneous immunometric fluorescent compound set can be used for detecting the low-value FABP and the high-value FABP, particularly the low-value FABP, is low in cost, simple, quick and sensitive to operate and good in specificity, only needs to be matched with a special homogeneous fluoroimmunoassay detection instrument, and therefore, the homogeneous immunometric fluorescent compound set can be widely applied to medical examination places at different levels, particularly basic-level medical mechanisms including health clinics in towns and townships and has great significance on preventing heart and cerebral vessel events.

The invention relates to the technical field of medical detection, in particular to a kit for detecting heart-type fatty acid binding proteins by a latex enhanced immune turbidimetry method. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 contains a Tris buffer solution and polyethylene glycol p-isooctyl phenyl ether, and has the pH of 7.0 to 8.0; the reagent R2 contains mouse-anti-human heart-type fatty acid binding protein monoclonal antibody latex particles, a Tris buffer solution, albumin bovine serum, alkyl glycoside APG0810, mannitol and polyethylene glycol p-isooctyl phenyl ether, and has the pH of 7.0 to 8.0. According to the kit disclosed by the invention, the ratios of the latex particles with different particle sizes are strictly defined, so that the sensitivity and the specificity of detection are improved; therefore, a surfactant and stabilizing agent combination suitable for the system is obtained; on the premise of high measurement speed and sensitivity and high specificity, the whole system is high in stability and easy and convenient to operate, and is suitable for being matched with a clinically full-automatic or semi-automatic biochemical analyzer in use.

The invention discloses a paper-based analysis device and a paper-based analysis method based on zinc oxide nanowire fluorescence enhancement. The device comprises a detection layer A and a sample adding layer B. The detection layer A comprises three detection areas which are used for detecting fatty acid binding protein FABP, cardiac troponin cTnI and myoglobin respectively. A sample is added tothe central area of the sample adding layer B, and then, the sample adding layer B is folded onto the detection layer A so that the sample is distributed to the three detection areas to realize simultaneous detection of fatty acid binding protein FABP, cardiac troponin cTnI and myoglobin. The paper-based analysis device and the paper-based analysis method disclosed by the invention can detect thethree myocardial markers at the same time and have high sensitivity and good selectivity for the detection of FABP, cTnI and myoglobin, and the detection limits of the three myocardial markers are 1.36ng/mL, 1.00ng/mL and 2.38ng/mL respectively.

The present invention relates to peptide fragments which have one or more shared and/or similar amino acid sequences to amino acid sequences of specific portions of the 14 kDa protein of S. mansoni (Sm14) or related FABPs (Fatty Acid Binding Proteins), the said peptide fragments functioning as continuous or discontinuous epitopic regions of the molecule or mimicking its biological activity. More particularly, the present invention relates to a method for constructing active peptide fragments, peptide fragments, immunogenic composition and diagnostic kit using said peptide fragments.

[Problem] To provide a method for the immunoassay of liver-type fatty acid-binding proteins (L-FABPs) in a sample using anti-L-FABP antibodies, said method exhibiting a good level of correlation and adetection sensitivity equivalent or superior to existing in-vitro diagnostic products. [Solution] The problem is solved by a method of detecting L-FABPs in a sample using anti-L-FABP antibodies, saidmethod including a step in which anti-L-FABP antibodies and a compound having a ring structure and a NH2-C=N- partial structure in the molecules thereof are brought into contact with a sample in which L-FABPs are suspected to be present.